Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYS: Telithromycin vs Azithromycin in Lower Respiratory Tract Infections
NCT00132951Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Oct 2004
- Primary completion
- Sep 2006
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of telithromycin in lower respiratory tract infection (LRTI), chronic bronchitis (CB) and community acquired pneumonia (CAP) (2 arms), sponsored by Sanofi. Primary endpoint: Post-treatment utilization of healthcare resources at 30 days. Started Oct 2004; status: terminated.
02
Drugs
telithromycin
03
Conditions
lower respiratory tract infection (LRTI)chronic bronchitis (CB)community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT00132951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132951.